-
mRNA-LNP Programming of CAR Macrophages
2026-09-25
Gu et al. describe an intraperitoneal mRNA-LNP approach for programming CAR macrophages and compare 36 CAR designs to identify constructs that promote inflammatory activity and adaptive immune responses. The findings connect CAR design with tumor-microenvironment remodeling and provide a rationale for combining tailored CAR macrophages with PD-1/PD-L1 blockade, while leaving clinical translation and delivery parameters to be established.
-
Gut LPS Structure Shapes Checkpoint Immunotherapy Response
2026-09-25
This study links the structure of gut microbiota-derived lipopolysaccharide (LPS), rather than bacterial taxonomy alone, to response to anti-PD-1 immunotherapy. Human metagenomic analyses and mouse experiments indicate that hexa-acylated LPS can support TLR4-dependent antitumour immunity, while hypo-acylated LPS may counteract that activity.
-
miR-424/503 Links TGF-β to CDC25A and Cell-Cycle Arrest
2026-09-24
The study identifies the miR-424(322)/503 cluster as a post-transcriptional component of TGF-β-induced cell-cycle arrest in mammary epithelial cells. By reducing CDC25A alongside transcriptional repression and protein degradation, this microRNA cluster helps strengthen the cytostatic response and influences hormone receptor-positive epithelial-cell proliferation in vivo.
-
EdU Imaging Kits (488): A Practical Assay Guide
2026-09-24
Learn how to use EdU Imaging Kits (488), SKU K1175, to measure S-phase DNA synthesis and interpret proliferation data alongside viability and cell-cycle assays. This scenario-based guide covers assay design, controls, imaging considerations, and the limits of translating cancer biology findings into an EdU readout.
-
Gemini QAC Derivatives: Broad-Spectrum Biocidal Activity
2026-09-23
The study reports 16 new octenidine-derived gemini quaternary ammonium compounds and compares their antimicrobial activity, cytotoxicity, and predicted membrane permeation. Several candidates showed activity across bacterial, fungal, and viral models; compounds 1 and 12 were notable for antifungal performance, while compound 12 combined broad activity with relatively low cytotoxicity.
-
GSH and GSSG Assay Kit for Tumor Redox Studies
2026-09-23
Translate hypoxia and immunometabolism into measurable redox endpoints by pairing total glutathione with selective GSSG analysis. This workflow supports reduced glutathione detection in tumor cells, immune-cell models, tissues, plasma, and red blood cells while preserving practical troubleshooting guidance.
-
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-22
This study compared six JAK inhibitors in cytokine-stimulated human endothelial cells and showed that suppressing IL-6 does not necessarily normalize adhesion, coagulation, or endothelial survival responses. The findings support concentration-aware interpretation of JAK inhibitor experiments and caution against treating anti-inflammatory activity as a complete surrogate for vascular protection.
-
Liproxstatin-1: A Ferroptosis Assay Compass
2026-09-22
Liproxstatin-1 is a ferroptosis inhibitor that helps distinguish lipid-peroxidation-driven death from downstream membrane failure. This guide uses recent TMEM16F research to show how B4987 can sharpen assay design, controls, and interpretation.
-
Sulfisomidine: A Dual-Pathway Assay Strategy
2026-09-21
Sulfisomidine, also known as sulfamethin, is more than a legacy antibacterial reagent. Its competitive interference with bacterial PABA utilization and mixed-type inhibition of human serum paraoxonase 1 create a practical bridge between microbial folate biology, enzyme kinetics, oxidative stress regulation research, and translational assay design.
-
XAV-939: From Wnt Mechanism to Translational Strategy
2026-09-21
XAV-939 connects tankyrase biology with practical translational decisions across cancer, fibrosis, synovial inflammation, and bone biology. This thought-leadership guide interprets the mechanistic evidence, positions the compound against common pathway-validation approaches, and outlines a disciplined workflow for moving from β-catenin modulation to disease-relevant endpoints.
-
PR-619: Practical Guide to DUB Inhibition
2026-09-20
PR-619 is a reversible, cell-permeable deubiquitylating enzymes inhibitor for mapping ubiquitinated-protein dynamics without directly blocking proteasomal catalytic activity. This guide connects dose planning, autophagy and cancer assays, neurodegeneration models, troubleshooting, and a recent HPV-positive cancer study to practical experimental workflows.
-
Masitinib (AB1010) Practical Protocol Guide
2026-09-19
This guide explains how to use Masitinib (AB1010), SKU A2942, in DMSO-based workflows examining KIT, PDGFRα, PDGFRβ, mast-cell responses, and selected KIT-mutant models. It is not intended for aqueous or ethanol-based protocols, broad-spectrum kinase screening, or clinical treatment decisions without independent evidence.
-
Carvedilol: Applied β-Adrenergic Research Workflows
2026-09-18
Carvedilol combines nonselective β-adrenergic blockade with α1-adrenergic antagonism and measurable antioxidant activity, making it useful across receptor-signaling, vascular, oxidative-stress, and hematopoietic assays. This practical guide connects concentration selection, vehicle control, transplant-model design, and troubleshooting to findings from recent regeneration research.
-
Tropifexor and the Gut–Liver Translation Gap
2026-09-18
Tropifexor (LJN452) gives translational researchers a highly potent, research-grade tool for testing how FXR activation shapes intestinal barrier biology and metabolic signaling. By placing FXR experiments alongside new evidence on triacetin digestion and hepatic AMPK responses, this article outlines a more rigorous strategy for connecting epithelial, hepatic, and nutrient-derived signals without overstating causality.
-
Gastric Cancer Assembloids Model Tumor–Stroma Biology
2026-09-17
The reference study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with autologous stromal cell subpopulations. Its results show that stromal composition alters gene expression and drug sensitivity, providing a more physiologically informative platform for resistance studies and personalized treatment evaluation.